A MODERN APPROACH TO T-CELL LYMPHOMA TREATMENT: DEMONSTRATING A THERAPEUTIC STRATEGY (A CLINICAL CASE)

作者：A. Jazyltayeva, S. Gabbasova, Z. Dushimova, R. Ramazanova, E. Satbaeva, I. Polyatskin, A. Shalabay, N. Zhappargaly · 发表于：Oncologia i radiologia Kazakhstana · 年份：2025 · DOI：10.52532/2521-6414-2025-2-76-500

Relevance: Primary central nervous system (PCCNS) lymphomas are a rare type of lymphoma, accounting for 2% of all CNS lymphomas, and are associated with a poor prognosis. According to data from the Republic of Kazakhstan EROB Information System, in 2023-2024, the «CNS lymphoma» diagnosis was morphologically confirmed in 13 individuals. Among primary CNS lymphomas, the ALK-negative subtype of anaplastic large-cell T-cell lymphoma is a highly malignant tumor with an aggressive clinical course. Treatment of such patients remains challenging, requiring an expanded evidence base and more clinical case reports. 17. Abid M.B., Wang S., Loi H.Y., Poon L.M. АЛК-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin // Ann Hematol. – 2016. – Vol. 95, No. 10. – P. 1725– 1726. https://doi.org/10.1007/s00277-016-2746-3 18. Li Y., Zeng R., Xia C., Li Y., He Y., Wang C., Zhou H. Brentuximab Vedotin-Based Treatment in Patients with CD30-Positive Lymphoma: A Retrospective Analysis // Blood. – 2024. – Vol. 144, No. 1. – P. 6465. https://doi.org/10.1182/blood-2024-204718 19. Delacruz W., Setlik R., Hassantoufighi A., Daya S., Cooper S., Selby D., Brown A. Novel brentuximab vedotin combination therapies show promising activity in highly refractory CD30+ non-Hodgkin lymphoma: A case series and review of the literature // Case Rep Oncol Med. – 2016. – Vol. 2016. – P. 1–7. https://doi.org/10.1155/2016/2596423 20. Mitsunobu T., Nishika...